

06 July 2021

Our Ref: RFI 39590

Dear

**Freedom of Information Act 2000
Information in relation to Colorectal Cancer.**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to above which you requested on 11 June 2021.

A response to each of the questions raised has been provided by the Hospital Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Rebecca Manning
Information Governance Assistant

Q1. Could you please tell us how many patients were treated in the last three months (for colorectal cancer) with the following agents:

A1. Please see Table 1

Table 1

Treatment	Number of Patients
Aflibercept	Nil
Bevacizumab	Nil
Capecitabine	17
CAPIRI	5
CAPOX (XELOX)	5
Cetuximab in combination with FOLFIRI	5
Cetuximab in combination with FOLFOX	<5
Cetuximab not in combination with FOLFIRI or FOLFOX	<5
Irinotecan only	Nil
FOLFIRI	<5
FOLFOX	7
Fluorouracil (5FU) only	Nil
Oxaliplatin only	Nil
Panitumumab in combination with FOLFIRI	Nil
Panitumumab in combination with FOLFOX	Nil
Panitumumab not in combination with FOLFIRI or FOLFOX	Nil
Nivolumab	Nil
Raltitrexed	<5 (in combination with oxaliplatin)
Ramucirumab	Nil
Regorafenib	Nil
Sorafenib	Nil
Other SACT	Nil

NB. You will note that some of the numbers have been masked and this is due to small numbers within a small geographical area.